Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale

Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale

Abstract Background Rituximab has become a standard treatment for non‐Hodgkin lymphoma. Clinical studies have demonstrated the efficacy of rituximab in combination with standard chemotherapies in the treatment of follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL) patients. This non‐i...

Full description

Bibliographic Details
Main Authors: Jan Dürig, Jens Uhlig, Anke Gerhardt, Markus Ritter, Gunnar Hapke, Jörg Heßling, Peter Staib, Frieder Wolff, Katja Krumm, Ludwig Fischer vonWeikersthal
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Medicine
Subjects:
complete response
diffuse large B cell lymphoma (DLBCL)
follicular lymphoma
non‐interventional study
progression‐free survival
subcutaneous rituximab
Online Access:https://doi.org/10.1002/cam4.5160

Internet

https://doi.org/10.1002/cam4.5160

Similar Items